IFNGR2 and neoplasm: To better align our mouse model with this clinical scenario, we found that when WT tumor cells were mixed with IFNγR2-mutant tumor cells and implanted in vivo, the IFNγR2-mutant cells were indeed selected out under strong immune pressure upon anti-PD-L1 therapy.